The biotech company Roche is receiving support towards its efforts to advance cancer diagnosis and digital pathology ...

The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA ...

While all steps in the IHC protocol affect the quality of the staining outcome, three important factors to consider during initial optimization are primary antibody selection, antigen retrieval, and ...

Small research labs that can't justify spending tens of thousands of dollars on a sophisticated automated immuno-histochemistry (IHC) staining system can still Courtesy of Chemicon International ...

US FDA grants breakthrough device designation to Roche’s companion diagnostic, VENTANA TROP2 (EPR20043) RxDx Device for non-small cell lung cancer: Basel Wednesday, April 30, 20 ...

The antibodies themselves are designed to work with tags that can be detected or seen under a microscope, such as fluorescent ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

The device helps identify NSCLC subjects who are likely to benefit from Daiichi Sankyo and AstraZeneca’s Datroway’s treatment ...

In recent years, the treatment landscape of HR+/HER2−ve breast cancer has completely changed with the introduction of particularly active targeted drugs, from CDK4/6 inhibitors, mTOR inhibitors, and ...

RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment. The device uses artificial intelligence-based image analysis with a level ...

Agilent (A) announced its PD-L1 IHC 22C3 pharmDx assay has received European IVDR certification for the use as a Companion Diagnostic to aid in ...